Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease
- PMID: 35566504
- PMCID: PMC9100167
- DOI: 10.3390/jcm11092380
Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease
Abstract
Percutaneous coronary intervention (PCI) is one of the most common procedures performed in medicine. However, its net benefit among patients with chronic kidney disease (CKD) is less well established than in the general population. The prevalence of patients suffering from both CAD and CKD is high, and is likely to increase in the coming years. Planning the adequate management of this group of patients is crucial to improve their outcome after PCI. This starts with proper preparation before the procedure, the use of all available means to reduce contrast during the procedure, and the implementation of modern strategies such as radial access and drug-eluting stents. At the end of the procedure, personalized antithrombotic therapy for the patient's specific characteristics is advisable to account for the elevated ischemic and bleeding risk of these patients.
Keywords: chronic kidney disease; contrast-induced nephropathy; percutaneous coronary intervention.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.JACC Cardiovasc Interv. 2009 Jan;2(1):37-45. doi: 10.1016/j.jcin.2008.06.012. JACC Cardiovasc Interv. 2009. PMID: 19463396 Clinical Trial.
-
Cardiovascular outcomes following percutaneous coronary intervention with drug-eluting balloons in chronic kidney disease: a retrospective analysis.BMC Nephrol. 2020 Oct 23;21(1):445. doi: 10.1186/s12882-020-02089-w. BMC Nephrol. 2020. PMID: 33097001 Free PMC article.
-
Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012. JACC Cardiovasc Interv. 2011. PMID: 21939942 Clinical Trial.
-
Management of acute coronary syndrome in chronic kidney disease.J Assoc Physicians India. 2012 Nov;60:48-51. J Assoc Physicians India. 2012. PMID: 23767202 Review.
-
Coronary artery disease in patients with chronic kidney disease: a clinical update.Curr Cardiol Rev. 2013 Nov;9(4):331-9. doi: 10.2174/1573403x10666140214122234. Curr Cardiol Rev. 2013. PMID: 24527682 Free PMC article. Review.
Cited by
-
Is It Safe to Do Percutaneous Coronary Intervention in Moderate to Severe Chronic Kidney Disease Patients? A Prospective Cohort Study.Cureus. 2022 Oct 14;14(10):e30312. doi: 10.7759/cureus.30312. eCollection 2022 Oct. Cureus. 2022. PMID: 36407165 Free PMC article.
-
Appropriateness of Percutaneous Coronary Interventions: A Systematic Review and Meta-Analysis.J Cardiovasc Dev Dis. 2023 Feb 21;10(3):93. doi: 10.3390/jcdd10030093. J Cardiovasc Dev Dis. 2023. PMID: 36975857 Free PMC article. Review.
-
A Simple Strategy to Reduce Contrast Media Use and Risk of Contrast-Induced Renal Injury during PCI: Introduction of an "Optimal Contrast Volume Protocol" to Daily Clinical Practice.J Cardiovasc Dev Dis. 2023 Sep 19;10(9):402. doi: 10.3390/jcdd10090402. J Cardiovasc Dev Dis. 2023. PMID: 37754831 Free PMC article.
-
Risk Factors of Suboptimal Coronary Blood Flow after a Percutaneous Coronary Intervention in Patients with Acute Anterior Wall Myocardial Infarction.J Pers Med. 2023 Jul 31;13(8):1217. doi: 10.3390/jpm13081217. J Pers Med. 2023. PMID: 37623467 Free PMC article.
-
Cardiovascular and bleeding risks of inactive cancer in patients with acute myocardial infarction who received primary percutaneous coronary intervention using drug-eluting stent and dual/triple antithrombotic therapy.Cardiovasc Diagn Ther. 2022 Dec;12(6):803-814. doi: 10.21037/cdt-22-306. Cardiovasc Diagn Ther. 2022. PMID: 36605075 Free PMC article.
References
-
- Caracciolo A., Mazzone P., Laterra G., Garcia-Ruiz V., Polimeni A., Galasso S., Saporito F., Carerj S., D’Ascenzo F., Marquis-Gravel G., et al. Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. J. Clin. Med. 2019;8:2016. doi: 10.3390/jcm8112016. - DOI - PMC - PubMed
-
- Spertus J.A., Jones P.G., Maron D.J., O’Brien S.M., Reynolds H., Rosenberg Y., Stone G.W., Harrell F.E., Boden W.E., Weintraub W.S., et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N. Engl. J. Med. 2020;382:1408–1419. doi: 10.1056/NEJMoa1916370. - DOI - PMC - PubMed
-
- Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E., Chaitman B.R., Senior R., López-Sendón J., Alexander K.P., et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N. Engl. J. Med. 2020;382:1395–1407. doi: 10.1056/NEJMoa1915922. - DOI - PMC - PubMed
-
- Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.-M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceDeveloped by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2021;42:3227–3337. doi: 10.1093/EURHEARTJ/EHAB484. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous